Phathom (PHAT) Q3 2026 Earnings Call Transcript

Phathom Pharmaceuticals reported Q3 2026 revenue of $84.7 million, up 71% year over year and 14% sequentially, and a second consecutive quarter of non-GAAP operating profit, at $5.8 million excluding stock-based compensation; cash from operations was about $2.1 million. The company maintained 2026 revenue guidance of $310 million-$325 million and reported $184.6 million in cash, while gross margin was 78%, below guidance because of one-time manufacturing charges. BDR Pharmaceuticals sued the FDA over VOQUEZNA's exclusivity, which the FDA currently recognizes through May 3, 2032; Phathom has intervened to defend that position.

Analysis

Core read

The operating inflection is encouraging, but the key underwriting question is whether access work converts into durable, incremental refills—not merely more prescriptions routed through BlinkRx. The commercial flywheel has a lag: new-to-brand scripts now can become multiple fills over coming quarters, so Q4 may understate any benefit while 2027 expectations are vulnerable if PA completion, fills, and persistence fail to improve. Management has not disclosed the channel conversion metrics needed to verify that mechanism. The $0 copay may reduce friction, but it applies only to eligible commercially insured patients and its claimed modest net-revenue cost is not yet independently measurable.

Cash generation lowers financing risk, not eliminates it: the roughly $66M gap between quarter-end cash and the RIFA cash-hold threshold is a meaningful cushion, while Q3 operating cash generation was small relative to the balance. Sustained growth and covenant compliance matter more than a single quarter of non-GAAP operating profitability. The litigation is a long-duration valuation risk: adverse exclusivity outcomes could shorten the protected commercialization window and weaken the rationale for acquiring assets, though the current suit is not itself a loss of exclusivity. Q4 EoE data are the nearer binary catalyst; pediatric exclusivity remains contingent on positive data, FDA agreement, and further trials.

A second PCAB could expand category awareness and help the incumbent, but that is not automatically a volume tailwind: payer leverage or competitor discounting could redirect economics before the market grows. Watch net sales per prescription and refill persistence, not prescription counts alone.

Key Decisions for Investors

• Avoid chasing the earnings reaction without valuation and channel data. Track BlinkRx share of new-to-brand scripts, PA approval/fill conversion, refill persistence, and net revenue per prescription; those are the tests of whether access investment is producing profitable demand.
• For a catalyst-oriented position, consider building PHAT exposure in stages around the Q4 EoE readout rather than taking full size beforehand. A convincing histology signal with supportive symptoms improves the expansion/exclusivity option value; weak or discordant data would remove that catalyst and argue for reducing exposure. Keep sizing modest given the legal and clinical event risk.
• Treat the FDA docket and BDR litigation as a watch item, not a near-term base-case impairment. Reassess promptly on an adverse FDA position or court ruling; the thesis is falsified if the protected period is materially curtailed. Separately, rising rebates or slowing covered-script/refill growth after a second PCAB launch would falsify the presumed category-awareness benefit.